NO985197D0 - Reparasjon og forebygging av fibrotiske lesjoner - Google Patents

Reparasjon og forebygging av fibrotiske lesjoner

Info

Publication number
NO985197D0
NO985197D0 NO985197A NO985197A NO985197D0 NO 985197 D0 NO985197 D0 NO 985197D0 NO 985197 A NO985197 A NO 985197A NO 985197 A NO985197 A NO 985197A NO 985197 D0 NO985197 D0 NO 985197D0
Authority
NO
Norway
Prior art keywords
repair
prevention
fibrotic lesions
fibrotic
lesions
Prior art date
Application number
NO985197A
Other languages
English (en)
Norwegian (no)
Other versions
NO985197L (no
Inventor
Solomon B Margolin
Original Assignee
Solomon B Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solomon B Margolin filed Critical Solomon B Margolin
Publication of NO985197D0 publication Critical patent/NO985197D0/no
Publication of NO985197L publication Critical patent/NO985197L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO985197A 1996-05-09 1998-11-06 Reparasjon og forebygging av fibrotiske lesjoner NO985197L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/647,006 US5716632A (en) 1989-11-22 1996-05-09 Compositions and methods for reparation and prevention of fibrotic lesions
PCT/US1997/007468 WO1997041830A1 (fr) 1996-05-09 1997-05-03 Reparation et prevention des lesions fibreuses

Publications (2)

Publication Number Publication Date
NO985197D0 true NO985197D0 (no) 1998-11-06
NO985197L NO985197L (no) 1998-11-06

Family

ID=24595333

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985197A NO985197L (no) 1996-05-09 1998-11-06 Reparasjon og forebygging av fibrotiske lesjoner

Country Status (11)

Country Link
US (1) US5716632A (fr)
EP (1) EP0902680A4 (fr)
JP (1) JP2000510467A (fr)
KR (1) KR20000010676A (fr)
AU (1) AU725637B2 (fr)
CA (1) CA2253919A1 (fr)
IL (1) IL126891A0 (fr)
NO (1) NO985197L (fr)
TR (1) TR199802273T2 (fr)
WO (1) WO1997041830A1 (fr)
ZA (1) ZA974041B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
ES2221365T3 (es) * 1998-03-17 2004-12-16 Solomon B. Margolin Composiciones y metodos topicos antisepticos.
EP1113798B1 (fr) 1998-09-18 2003-01-02 Mepha AG Formulation topique a base d'alkyl-, phenyl-pyridone
EP1242084B1 (fr) * 2000-01-24 2006-07-05 MARGOLIN, Solomon B. Traitement de carcinomes mammaires, d'astrocytomes, de melanomes et de tumeurs apparentees
DE10053870A1 (de) * 2000-10-31 2002-05-08 Burchardt Elmar Reinhold Procollagen (III)-Propeptide und verwandte Substanzen zur Behandlung von fibrotischen Erkrankungen
WO2002060446A1 (fr) 2001-01-29 2002-08-08 Shionogi & Co., Ltd. Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif
US20060110358A1 (en) * 2002-08-28 2006-05-25 Hsu Henry H Combination therapy for treatment of fibrotic disorders
TW200418516A (en) * 2003-02-21 2004-10-01 Shionogi & Co Droplet dispersed ointment
EP1599171A2 (fr) * 2003-02-28 2005-11-30 Intermune, Inc. Therapie combinee servant a traiter une infection par un alphavirus et une fibrose hepatique
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
WO2004103296A2 (fr) * 2003-05-16 2004-12-02 Intermune, Inc. Methodes de traitement d'une fibrose pulmonaire idiopathique
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
CA2545813C (fr) * 2003-11-14 2011-01-04 Shanghai Genomics, Inc. Derives de pyridone, et utilisation correspondante
CA2576030A1 (fr) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
CN102816170A (zh) 2005-07-25 2012-12-12 因特蒙公司 C型肝炎病毒复制的新颖大环抑制剂
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
AU2006301966A1 (en) 2005-10-11 2007-04-19 Array Biopharma, Inc. Compounds and methods for inhibiting hepatitis C viral replication
JP2009513576A (ja) * 2005-10-11 2009-04-02 インターミューン・インコーポレーテッド ウィルス複製のインヒビター
WO2007143597A2 (fr) * 2006-06-05 2007-12-13 Novartis Ag Composés organiques
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
US20090047246A1 (en) * 2007-02-12 2009-02-19 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CN101472588A (zh) * 2007-04-27 2009-07-01 达瑞科技投资有限公司 5－甲基－1－(取代苯基)－2－(1H)吡啶酮化合物作为抗炎药物和α－肿瘤坏死因子(TNF－α)阻断剂的应用
KR20100024920A (ko) 2007-05-03 2010-03-08 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 마크로사이클릭 저해제
EP2185524A1 (fr) * 2007-05-10 2010-05-19 Intermune, Inc. Nouveaux inhibiteurs peptidiques de la réplication du virus de l'hépatite c
MX2007009796A (es) * 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
EP2219650B1 (fr) * 2007-10-26 2014-05-07 Pacific Therapeutics Ltd. Compositions et procédés permettant de traiter des troubles fibroprolifératifs
EP2262501B1 (fr) * 2008-03-07 2014-08-13 Solanan, Inc. Traitement d' une septicémie avec 5-éthyl-1-phényl-2(1h)-pyridone
CA3034994A1 (fr) * 2008-06-03 2009-12-10 Intermune, Inc. Composes et procedes de traitement des troubles inflammatoires et fibrotiques
WO2010045266A1 (fr) 2008-10-15 2010-04-22 Intermune, Inc. Peptides antiviraux therapeutiques
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
KR20110114684A (ko) * 2009-01-26 2011-10-19 인터뮨, 인크. 급성 심근 경색 및 연관된 질환을 치료하는 방법
CN102149682B (zh) 2009-05-25 2012-12-05 中南大学 1-(取代芳基)-5-三氟甲基-2-（1h）吡啶酮化合物及其盐的制备方法及其用途
DK2474533T3 (en) 2009-05-25 2015-05-18 Univ Central South Preparation of 1- (substituted benzyl) -5-TRIFLUOROMETYL-2- (1H) pyridone compounds and their salts and their use
EP2483290A4 (fr) 2009-09-28 2013-05-01 Intermune Inc Inhibiteurs peptiques cycliques de la réplication du virus de l'hépatite c
EP2496944A2 (fr) 2009-11-05 2012-09-12 Novartis AG Marqueurs biologiques prédictifs de l'évolution d'une fibrose
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2012107831A1 (fr) 2011-02-11 2012-08-16 Signa S.A. De C.V. Procédé de fabrication d'un composé de pyridone, 5-éthyl-1-phényl-2-(1h)-pyridone, et ses intermédiaires
CA2819967C (fr) * 2012-08-31 2016-03-22 Intermune, Inc. Utilisation de pirfenidone en simultanee avec du ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9587235B2 (en) * 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
AU2018256435A1 (en) * 2017-04-20 2019-11-07 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN114716365B (zh) * 2022-01-04 2024-03-01 大连理工大学 一类n-取代苯基-2-吡啶酮化合物或其可药用盐在治疗肺纤维化中的应用
CN114805333A (zh) * 2022-05-09 2022-07-29 大连理工大学 一种主链含噁嗪和Cardo结构的双马来酰亚胺及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (fr) * 1972-12-18 1979-02-27 Affiliated Medical Research Pyridone n-substituee; methode generale de synthese des pyridones
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5518729A (en) * 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
BR9406461A (pt) * 1993-05-07 1996-01-30 Solomon Begelfor Margolin Composições e métodos para a reparação e prevenção de les~es fibróticas
US5789426A (en) * 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
EP0813409B1 (fr) * 1995-03-03 2004-05-06 MARGOLIN, Solomon B. Traitement des troubles provoques par les facteurs de croissance a cytokine
WO1997010712A1 (fr) * 1995-09-19 1997-03-27 Margolin Solomon B INHIBITION DU FACTEUR α DE NECROSE TUMORALE

Also Published As

Publication number Publication date
KR20000010676A (ko) 2000-02-25
JP2000510467A (ja) 2000-08-15
ZA974041B (en) 1998-11-09
AU725637B2 (en) 2000-10-19
WO1997041830A1 (fr) 1997-11-13
US5716632A (en) 1998-02-10
TR199802273T2 (xx) 2000-11-21
AU2751997A (en) 1997-11-26
EP0902680A4 (fr) 2000-04-19
CA2253919A1 (fr) 1997-11-13
IL126891A0 (en) 1999-09-22
EP0902680A1 (fr) 1999-03-24
NO985197L (no) 1998-11-06

Similar Documents

Publication Publication Date Title
NO985197D0 (no) Reparasjon og forebygging av fibrotiske lesjoner
PT946323E (pt) Pos de niobio e condensadores eletroliticos de niobio
NO991676D0 (no) FremgangsmÕter og sammensetninger for immunmodulering
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
NO973464D0 (no) Forlengingsrör - avskraperpluggapparat og fremgangsmåte
NO953991D0 (no) Ultrasomisk og elektro-kirurgisk håndstykke av piezotype
NO992297L (no) FremgangsmÕte og nye forbindelser
GB2319839B (en) Signal amplification method and kit
NO990700D0 (no) Propionsyrederivater og anvendelsen herav
NO984947D0 (no) Avisingsmiddel og fremgangsmÕte ved anvendelse av dette
DE69713202D1 (de) Einführungsvorrichtungen sowie Anordnungen
PL318128A1 (en) Polymer-polyol and method of obtaining polymer-polyols
NO972072D0 (no) Oppblåsbar pakning
DK0906301T3 (da) Benzofurylderivater og anvendelsen deraf
GB9600276D0 (en) Inflatable speculum
NO983512D0 (no) Midler for behandling og forhindring av AIDS
FR2747557B3 (fr) Stethoscope
NO983519L (no) OppblÕsbar pakning
NO992082L (no) Fremgangsmate for spredning av take og installasjon derav
NO970597D0 (no) Line- og wirekopling
ID16821A (id) Perbaikan kerusakan
AU1853397A (en) Treatment of pulmonary inflammation
NO983556L (no) Formulering og anvendelse
DE69729092D1 (de) Mit fluor markierte anthracyclin und -anthracyclinon derivate
NO990018D0 (no) Belegg og fremgangsmÕte for fremstilling derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application